New UCL-led research, published in Nature Medicine
One of the largest real-world evaluations of GLP-1 therapy ever published: 8,127 women followed over six months.
Independently analysed by University College London. Delivered through eMed's digital care programme.
“This study provides some of the most comprehensive real-world evidence to date on GLP-1 treatment in women. What's particularly striking is the consistency of outcomes across a large and diverse population.”
GLP-1 receptor agonist therapy delivered within a structured digital programme was associated with clinically meaningful weight loss, metabolic improvement and high treatment retention in a large community-based cohort of women.
Percentage of participants reaching each threshold
From 104.6 kg at the start to 88.6 kg at six months.
Crossing from class II to class I obesity on average.
More than nine in ten women were still on treatment at six months. Discontinuation was 5.0% among those using structured side-effect support, against 7.4% without.
still on treatment at six months
Weight loss comparable to that seen in the original clinical trials, but delivered at lower average doses, leading to lower risk of side effects.
Average dose exposure across the study sat at around 63% of the maximum licensed dose.
of those with diabetes-range blood sugar returned to the normal range
of those with prediabetes returned to the normal range
Total cholesterol: all cholesterol-carrying particles in the blood.
LDL cholesterol: the "bad" cholesterol that builds up in arteries.
Triglycerides: fats in the blood linked to heart and liver disease.
Serious treatment-related adverse events
of reported side effects were mild or moderate
of participants came from lower socioeconomic backgrounds
across every ethnicity in the study
Published in Nature Medicine. The study was led and analysed independently by University College London.
91.4% were still on treatment at six months. Discontinuation was lower among those using structured side-effect support (5.0% vs 7.4%).
Average dose exposure across the study sat at around 63% of the maximum licensed dose, and weight loss over six months was comparable to the trajectories reported in the major clinical trials of these treatments.
84.5% of those in the diabetes range and 96.3% of those with prediabetes returned to normal blood sugar. Average total cholesterol moved into the healthy range.
No significant difference in weight loss by deprivation level, and results held at every age from 18 to 79. There were no serious treatment-related adverse events.
Many employees are already using GLP-1 medication, often through routes with no screening, monitoring or aftercare. A governed programme ensures patient safety, better adherence to the medication, better results and maximises value for money.
Employers receive aggregated, anonymised reporting on weight loss, HbA1c, cholesterol and BMI. No individual clinical data is shared.
We can guide your reward, benefits or clinical governance team through the published findings, the reporting you would receive and how the programme could be delivered to your employees.
Managing Director, UK
Chief Clinical and Strategy Officer
Chief Medical Officer
partnershipsuk@emed.com
A 30-minute conversation with our clinical and commercial leads.
Further explanations can be provided upon request via email, or with a meeting.
Please reach out if you'd like to understand how GLP-1 weight loss programmes can be offered as an employee benefit.
A defined cohort with an agreed measurement framework set at baseline.
A CQC-registered service with UK-registered prescribers, delivering structured, clinician-led GLP-1 care remotely across the UK. The programme evaluated in this research is operated by eMed Healthcare UK together with SheMed.
Prescription treatment is not suitable for everyone and is only provided following clinical assessment, including mandatory blood testing. This page is intended for employers, insurers, occupational health teams and commissioners.
Deanfield J, Wong JLC, Katsoulis M, Deanfield E, Thakkar R, Patel R, Joy R, Noble M, Ryan DH. Real world, digital-first delivery of GLP-1 receptor agonist therapy in women. Nature Medicine, 2026. n = 8,127 women, six-month outcomes. All outcome figures on this page are drawn from this publication. Dot and square visualisations use actual participant numbers where feasible; the prediabetes grid uses proportional representation.